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Abstract: The aim of this study was to apply molecular epidemiology, antimicrobial surveillance,
and PK/PD analysis to guide the antimicrobial treatment of gonococci infections in a region of the
north of Spain. Antibiotic susceptibility testing was performed on all isolates (2017 to 2019, n = 202).
A subset of 35 isolates intermediate or resistant to at least two antimicrobials were selected to
search for resistance genes and genotyping through WGS. By Monte Carlo simulation, we estimated
the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the
antimicrobials used to treat gonorrhea, both indicative of the probability of treatment success. In
total, 2.0%, 6.4%, 5.4%, and 48.2% of the isolates were resistant to ceftriaxone, cefixime, azithromycin,
and ciprofloxacin, respectively. Twenty sequence types were identified. Detected mutations were
related to antibiotic resistance. PK/PD analysis showed high probability of treatment success of
the cephalosporins. In conclusion, multiple populations of N. gonorrhoeae were identified. We can
confirm that ceftriaxone (even at the lowest dose: 250 mg) and oral cefixime are good candidates to
treat gonorrhea. For patients allergic to cephalosporins, ciprofloxacin should be only used if the MIC
is known and ≤0.125 mg/L; this antimicrobial is not recommended for empirical treatment.
Keywords: N. gonorrhoeae; antibiotic resistance; cephalosporins; azithromycin; pharmacokinetic/
pharmacodynamic (PK/PD) analysis; whole-genome sequencing (WGS)
1. Introduction
Sexually transmitted infections (STIs) are a serious global health problem [1]. The
prevalence of gonorrhea has increased significantly in recent years. The World Health
Organization (WHO) estimates that there are 87 million new cases of gonorrhea each
year [2].
In recent years, the most frequently prescribed antibiotics for the treatment of gonor-
rhea have become less effective, in part due to the inexorable progression of gonococcal
antimicrobial resistance [3,4]. In 2018, the WHO reported the expansion of multidrug-
resistant strains of N. gonorrhoeae worldwide [5]. In Europe, the Euro-GASP (depending
on the European Centre for Disease Prevention and Control) provides important data
at the European level on antimicrobial resistance, which are used to inform treatment
guidelines [6]. Thus, the determination of antimicrobial susceptibility to identify isolates
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with less susceptibility and resistance to antimicrobial agents, and monitoring of strain
populations via molecular techniques to identify gonococcal clones that are important for
driving the transmission of multidrug-resistant gonococci, become crucial. Additionally,
ensuring effective empirical therapy is also essential.
Current guidelines—such as the European guidelines for the diagnosis and treatment
of gonorrhea in adults [7], and the Center for Disease Control and Prevention (CDC)
Treatment Guidelines for Gonococcal Infection [8], both from 2020—recommend a dual
therapy with extended-spectrum cephalosporins (ESCs, such as ceftriaxone or cefixime)
and azithromycin for the treatment of uncomplicated gonorrhea when the antimicrobial
susceptibility is unknown. Some guidelines recommend fluoroquinolones as an alternative
treatment of pharyngeal infections if the isolate is known to be fluoroquinolone-susceptible
and there are indications against using ceftriaxone—for instance, history of severe hyper-
sensitivity to cephalosporins [7,9].
Recently, improved methods for the evaluation of the effects of pharmacokinetics (PK)
and pharmacodynamics (PD) on treatment outcomes have become available for a number
of other infections. In this regard, better data and new research on PK contributors to
gonorrhea treatment outcomes are needed [10]. PK/PD analysis integrates information
about the concentration of the drug that reaches the infection site and induces the thera-
peutic response, and the susceptibility of the pathogen to the antibiotic, expressed as the
minimum inhibitory concentration (MIC). This allows researchers or clinicians to select
the optimal antibiotic and dosing regimen for each infectious process and patient in order
to enhance the effect of the antibiotic, minimizing the incidence of side effects and the
emergence of resistance [11].
The aim of this work was to apply molecular epidemiology—including whole-genome
sequencing (WGS) information, antimicrobial surveillance data, and PK/PD analysis—to
guide the antimicrobial treatment of gonococci infections.
2. Materials and Methods
2.1. N. gonorrhoeae Isolates
All isolates from 2017 to 2019 were collected at the Microbiology Service of the Univer-
sity Hospital of Araba (HUA). The hospital, located in the Basque Country (Spain), covers
a population of ~400,000 inhabitants, and has 780 beds.
Non-duplicated N. gonorrhoeae isolates from patients attending to the Emergency,
Infectious Disease, and Primary Care services were included in the study. Gonococcal
isolation was performed on chocolate agar PolyViteX VCA and Chocolate agar PVX plates
(bioMérieux, Marcy-l’Étoile, France). The suspected colonies were then identified by
mass spectrometry using the MALDI-TOF MS (Microflex LT, Bruker-Daltonics, Bremen,
Germany) methodology [12].
This study met the exemption criteria of the ethics committee of clinical research
because the isolates analyzed were collected in routine practice, and did not allow the
identification of patients.
2.2. Antibiotic Susceptibility Testing
Isolated strains were subjected to antibiotic susceptibility testing using the MIC gra-
dient strip tests (Liofilchem, Roseto degli Abruzzi, Italy) according to the manufacturer’s
instructions. The minimum inhibitory concentrations (MICs) of tetracycline, penicillin,
cefixime, ceftriaxone, ciprofloxacin, and azithromycin were determined. From the MIC
distribution data of all of the isolates, the calculation of MIC50 and MIC90—i.e., the
lowest concentration of the antimicrobial capable of inhibiting 50% and 90% of the iso-
lates, respectively—was performed. Resistance rates were calculated with reference to
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [13] and the
Clinical and Laboratory Standards Institute (CLSI) [14]. The current EUCAST MIC break-
points for penicillin are ≤0.06 mg/L (susceptible) and >1 mg/L (resistant); for ceftriaxone
and cefixime, ≤0.125 mg/L (susceptible) and >0.125 mg/L (resistant); for ciprofloxacin,
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≤0.03 mg/L (susceptible) and >0.06 mg/L (resistant); and for tetracycline, ≤0.5 mg/L (sus-
ceptible) and >1 mg/L (resistant). For azithromycin, the EUCAST epidemiological cutoff
(ECOFF) of 1 mg/L was used to identify non-wild-type (WT) isolates. CLSI breakpoints
were the following: for penicillin, ≤0.06 mg/L (susceptible), 0.12–1 mg/L (intermedi-
ate), and ≥2 mg/L (resistant); for ceftriaxone and cefixime, ≤0.25 mg/L (susceptible);
for azithromycin, ≤1 mg/L (susceptible); for ciprofloxacin, ≤0.06 mg/L (susceptible),
0.12–0.5 mg/L (intermediate), and ≥1 mg/L (resistant); and for tetracycline, ≤0.25 mg/L
(susceptible), 0.5–1 mg/L (intermediate), and ≥2 mg/L (resistant).
2.3. WGS Molecular Epidemiology and Antimicrobial Resistance Determinants
A subset of 35 strains intermediate or resistant to at least two of the antimicrobials
tested were selected to search for resistance genes and genotyping through WGS. The DNA
of the strains was extracted using the NucleoSpin Tissue Kit (Macherey-Nagel, Duren,
Germany) and sequenced using the Illumina MiSeq platform with the Nextera DNA Flex
Library Prep Kit (Illumina, San Diego, CA, USA). The genomic information was received
as small nucleotide sequence reads, and longer sequences as contigs. These sequence data
were submitted to GenBank under the BioProject accession number PRJNA684048 (https://
www.ncbi.nlm.nih.gov/sra/PRJNA684048, accessed on 10 December 2020). Subsequently,
the assembled genomes of the isolates were input to the ResFinder 3.2 tool on the CGE
website (https://cge.cbs.dtu.dk, accessed on 10 December 2020) for the identification of
acquired antimicrobial resistance genes and chromosomal mutations. Default thresholds of
90% identity and 60% gene coverage were employed. Additionally, the PubMLST tool was
employed to detect antimicrobial resistance determinants (https://pubmlst.org/neisseria/,
accessed on 10 December 2020). Multilocus sequence typing (MLST) and N. gonorrhoeae
multi-antigen sequence typing (NG-MAST) were performed on the sequences produced
by WGS, and they were compared with existing alleles on the Neisseria MLST website
(http://pubmlst.org/neisseria/, accessed on 10 December 2020) and NG-MAST (http:
//www.ng-mast.net/, accessed on 10 December 2020) schemes for the determination of
allele numbers and sequence types (STs). All new alleles or STs were submitted to the
NG-MAST or MLST website curators to be assigned an allelic number and ST. The genomic
epidemiology of the isolates was determined based on whole-genome analysis. An SNP
phylogenetic tree, based on FASTQ files, was generated by using the default settings of the
MINTyper 1.0 server, available at https://cge.cbs.dtu.dk/services/MINTyper/ (accessed
on 10 December 2020). The complete genome of isolate FA1090 (NC_002946.2) was used as
a reference. Furthermore, a genome-based clustering was also performed using the TYGS
platform, accessible at https://tygs.dsmz.de/ (accessed on 10 December 2020).
2.4. Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis
In order to predict the probability of PK/PD target attainment, different antibiotics
and dosing regimens were evaluated (Table 1).
Table 1. Dose regimen, PK/PD index, and pharmacokinetic parameters used for simulations.
Ciprofloxacin Azithromycin Ceftriaxone Cefixime
Dose regimen 500 mg
single dose, PO
1 g, 2 g
single dose, PO








f T>MIC ≥ 20 h (IM)
f T>MIC ≥ 60% (IV)
f T>MIC ≥ 60%
AUC0–∞ (mg h/L) 10.7 ± 2.6
CL/F (L/h) 144 ± 39.5
Ke (h−1) 0.082 ± 0.029 0.204 ± 0.02
Vd (L) 14.70 ± 4.93 19 ± 0.03
Fu 0.05 0.35
F 1 0.42 ± 0.045
Ka (h−1) 1 0.55
References [15,16] [17,18] [19] [19]
IM: intramuscular; IV: intravenous; PO: oral; AUC0–∞: area under the plasma concentration vs. time curve from 0 to infinity; CL: clearance;
F: bioavailability; Fu: unbound fraction; Ka: absorption constant rate; Ke: elimination constant rate; Vd: volume of distribution.
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From the published pharmacokinetic parameters listed in Table 1 [15–19], and from
the study sample MIC distribution, we estimated the probability of target attainment
(PTA, defined as the probability that at least a specific value of a PK/PD index is achieved
at a certain minimum inhibitory concentration) and calculated the cumulative fraction
of response (CFR, defined as the expected population probability of target attainment
for a specific drug dose and a specific population of microorganisms). PK/PD indices
and values related to efficacy are also listed in Table 1. Five-thousand-subject Monte
Carlo simulations with Oracle® Crystal Ball Fusion Edition v.11.1.2.3.500 (Oracle USA Inc.,
Redwood City, CA, USA) were used to estimate the PTA and CRF values, indicative of
the probability of target success. PTA and CFR ≥ 80% but < 90% were associated with
moderate probabilities of success, whereas a CFR ≥ 90% was considered optimal against
that bacterial population. More detailed information about the PTA and CFR calculations
is presented in the Supplementary Materials.
3. Results
3.1. N. gonorrhoeae Isolates and Antibiotic Susceptibility Testing
A total of 202 isolates of N. gonorrhoeae were collected in the study period (2017–2019).
Of these, 85% were collected from men, and 15% from women. In men, the urethral
exudate was the most common sample (87%); other locations were anal exudate (11%) and
pharyngeal exudate (2%). Endocervical (64%) and vaginal exudate (33%) were the most
common among women, and anal exudate (1%) was also detected. The average age was
31 years (range 14–67) and 33 years (age range 16–61) for men and women, respectively. A
total of 10 patients had N. gonorrhoeae-positive cultures in two anatomical sites (7 pharynx
and rectum, 3 pharynx and urethra), but only one isolate per patient was included in the
susceptibility study.
Table 2 shows the antimicrobial susceptibility of N. gonorrhoeae isolates. The higher
resistance rates were obtained for ciprofloxacin and tetracycline. Eleven isolates were
resistant to azithromycin (5.4% of the total), all of which were collected in 2019. Resistant
isolates had MICs of 1.5 mg/L (n = 5), 2 mg/L (n = 5), and 16 mg/L (n = 1). The percentage
of isolates resistant to cephalosporins varied depending on the EUCAST and CLSI clinical
breakpoints: for cefixime, resistance rates were 6.4% (EUCAST) and 1.6% (CLSI), and for
ceftriaxone they were 2.0% (EUCAST) and 0.5% (CLSI). The MIC distribution of the six
antibiotics is presented in Figure S1.










Penicillin 0.002–64 0.19 3 12.6 12.6
Cefixime 0.008–0.75 0.008 0.047 6.4 1.6
Ceftriaxone 0.002–0.5 0.008 0.094 2.0 0.5
Azithromycin 0.016–16 0.19 0.75 5.4 a 5.4
Ciprofloxacin 0.015–64 0.012 8 48.2 45.2
Tetracycline 0.9->256 1 32 34.2 34.2
MIC: minimum inhibitory concentration; MIC50 and MIC90: minimum inhibitory concentration at which 50%
and 90% of the isolates were inhibited, respectively; R: percentage of resistant isolates. a: According to the
epidemiological cutoff (ECOFF) value.
3.2. Genotyping: MLST and NG-MAST
MLST genotyping identified multiple distinct populations of N. gonorrhoeae in the
isolates of HUA in 2017–2019 (Table 3). Overall, a total of 20 MLST STs were identified
among the 35 isolates analyzed, with ST-9363 being the most common (n = 8), followed by
ST-7363 (n = 4) and ST-7822 (n = 3), while 14 STs were represented by a single isolate. Two
new MLST STs (ST-14274 and ST-14304) were previously unreported, and resulted from
combinations of known alleles. NG-MAST further discriminated between strains with
identical MLST-STs, and 27 different NG-MAST STs were observed among the 35 isolates
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analyzed. ST-6765 predominated (n = 7), ST-470 and ST-13070 were observed in two isolates,
and the remaining STs were represented by single isolates. Additionally, six NG-MAST STs
(17.1%) were previously unreported, and resulted from new combinations of known alleles.
3.3. Antimicrobial Resistance Determinants
Genomic markers associated with resistance to ciprofloxacin, tetracycline, β-lactams,
and azithromycin were found (Table 3). All of the ciprofloxacin-resistant strains investi-
gated presented two substitutions in GyrA and one or two substitutions in ParC. At GyrA,
they presented substitutions in positions 91 (all presented an S91F) and 95 (D95A/G/N).
The main amino acid substitution observed in ParC was S87R (n = 13), either alone, or
associated with S88P. Other substitutions included D86N and E91G.
The tetM gene was detected in the four highly tetracycline-resistant strains
(MIC ≥ 24 mg/L). The V57M substitution in the ribosomal protein S10 subunit encoded
by the rpsJ gene was detected in 33/35 (94.3%) of the strains investigated, irrespective of
their tetracycline susceptibility. Chromosomal mutations in the porB gene were also found
in tetracycline-resistant strains. The G120K substitution was detected in 14 isolates, and
was associated with A121G/N/D.
The only sequenced isolate resistant to ceftriaxone (MIC: 0.25 mg/L) presented the
penA mosaic allele XXXIV associated with an L421P substitution in PBP1, a G120K/A121N
in the PorB, and an adenine deletion (-35A Del) in the mtrR promoter.
Twenty-five isolates showed different degrees of penicillin resistance. The four high-
level penicillin-resistant strains (n = 4; MIC ≥ 2 mg/L) carried the blaTEM-1B gene, which
encodes the TEM-1 β-lactamase; these four strains were β-lactamase producers, as de-
termined by the nitrocefin test. The remaining isolates (n = 21) presented an MIC range
between 0.19 and 0.75 mg/L. Nineteen isolates were associated with non-mosaic penA
alleles, with non-mosaic II being the most common (n = 10); the remaining six isolates
were associated with mosaic penA alleles (mosaic X and XXXIV, n = 3 each). The major
amino acid substitution observed in the PBP1 protein was Leu421Pro (n = 13), which
was correlated with a degree of intermediate resistance. Simultaneous substitutions at
amino acids G120 and A121 in the PorB porin—associated with decreased intake of several
antimicrobials—were observed in 16 penicillin-resistant isolates, with the substitutions of
G120K/A121N being the most common (n = 10).
The 13 isolates with an MIC of 1–2 mg/L against azithromycin were associated
with mutations in the promoter region and coding sequence of the mtrR genes, and with
mutations in the gene encoding the 23S rRNA. Two isolates presented the C2599T mutation
in the 23S rRNA gene associated with a G45D substitution in the MtrR protein. A deletion
of one guanine (G), 20 nucleotides downstream of the -35A deletion, was observed in
the mtrR promoter of 11 isolates; their sequences showed a 98.48% identity with that
of strain 38,194 (GenBank accession number KT954125), and 86.36% with strain FA1090
(GenBank accession number NC_002946). The -35A deletion in the repeated sequence of
the mtrR promoter was not observed in the resistant isolates; however, it was observed in
six susceptible isolates (MIC, <0.5 mg/L) as the only mechanism related to azithromycin
resistance. In the MtrR protein, the amino acid substitutions of A39T (n = 3) and G45D
(n = 2) were detected in azithromycin-resistant strains. The alignment of partial sequences
is presented in Supplementary Figure S2.
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Table 3. Genotypes, MICs, and antimicrobial resistance determinants for the 35 Neisseria gonorrhoeae isolates sequenced by WGS.
Genotype Susceptibility (mg/L) Chromosomal Mutations
Isolate Year MLST NG-MAST P CRO CFM TET CIP AZM
Adquired





2 2017 10,314 12,547 0.25 0.016 nd 0.5 3 0.125 - Type V non-mosaic L421P - S91F,D95A S87R V57M - A39T -
3 2017 1588 3750 0.38 0.023 nd 64 8 0.125 tet(M) Type XIX non-mosaic L421P G120KA121G
S91F,
D95A S87R V57M - A39T -
6 2017 1596 19,728 0.125 0.008 nd 0.125 0.006 0.25 - Type 81 semi Mosaic - - - - - - - -
9 2017 1583 19,729 0.125 0.006 nd 0.25 0.004 0.125 - Type II non-mosaic L421P - - - - -35A Del - -
11 2017 14,274 587 0.19 0.008 nd 0.5 0.006 0.75 - Type II non-mosaic - - - - V57M G - -
17 2017 1587 13,971 >32 0.012 nd 24 1.5 0.094 blaTEM-1B,tet(M) Type II non-mosaic - -
S91F,
D95A D86N V57M - - -
19 2017 10,935 15,728 2 0.006 nd 24 0.003 0.032 blaTEM-1B,tet(M) Type XIV non-mosaic - - - - V57M - - -
24 2017 8145 19,730 2 0.004 nd 0.5 0.004 0.125 blaTEM-1B Type XIV non-mosaic - - - - V57M - - -




S88P V57M - - -




S88P V57M - - -
35 2017 8143 14,306 0.125 0.008 nd 1 8 0.125 - Type II non-mosaic - S91F,D95A S87R V57M - A39T -




S88P V57M - - -
51 2018 7363 9184 0.38 0.064 nd 1.5 8 0.25 - Type IX non-mosaic L421P G120KA121D
S91F,
D95G E91G V57M -35A Del - -
52 2018 1901 1407 0.75 0.25 nd 3 >32 0.5 - Type XXXIV mosaic L421P G120KA121N
S91F,
D95G S87R V57M -35A Del - -
56 2018 10,890 1407 0.5 0.125 nd 4 >32 0.5 - Type XXXIV mosaic L421P G120K,A121N
S91F,
D95G S87R V57M -35A Del - -
58 2018 1901 19,111 0.5 0.125 nd 2 >32 0.5 - Type XXXIV mosaic L421P G120K,A121N
S91F,
D95G S87R V57M -35A Del - -




D95G D86N V57M - G45D -
61 2018 7363 15,198 0.25 0.064 nd 2 8 0.25 - Type IX non-mosaic L421P - S91F,D95G E91G V57M -35A Del - -
7244 2018 11428 2992 0.025 0.008 <0.016 0.25 0.016 0.75 - Type II non-mosaic - - - - V57M - A39T -
8661 2018 15,573 17,371 0.125 0.012 0.016 2 0.016 1 - Type II non-mosaic - G120K,A121N - - V57M G - -
293 2019 9363 6765 0.19 0.012 <0.016 2 0.012 1 - Type II non-mosaic - G120K,A121N - - V57M G - -
1941 2019 1580 470 0.125 0.03 0.016 2 0.002 1.5 - Type 93 semi Mosaic - A121S - - V57M - G45D C2599T
1943 2019 1580 470 0.125 0.008 <0.016 2 0.002 1.5 - Type 93 semi Mosaic - A121S - - V57M - G45D C2599T
3023 2019 9363 6765 0.25 0.016 <0.016 1.5 0.008 2 - Type II non-mosaic - G120K,A121N - - V57M G - -
3526 2019 9363 6765 0.19 0.023 <0.016 3 0.008 0.75 - Type II non-mosaic - G120K,A121N - - V57M G - -
3569 2019 9363 6765 0.38 0.012 <0.016 2 0.016 2 - Type II non-mosaic - G120K,A121N - - V57M G - -
3700 2019 11,706 17,972 0.19 0.003 <0.016 1.5 2 0.75 - Type V non-mosaic L421P - S91FD95A S87R V57M - A39T -
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Table 3. Cont.
Genotype Susceptibility (mg/L) Chromosomal Mutations
Isolate Year MLST NG-MAST P CRO CFM TET CIP AZM
Adquired





4458 2019 13,292 9208 0.094 0.004 nd 2 0.003 0.75 - Type II non-mosaic - - - - V57M - A39T C2611T
4515 2019 9363 6765 0.38 0.016 0.032 1 0.008 1.5 - Type II non-mosaic - G120K,A121N - - V57M G - -
4726 2019 9363 6765 0.19 0.016 <0.016 3 0.008 1 - Type II non-mosaic - G120K,A121N - - V57M G - -
5903 2019 7822 14,994 0.25 0.023 <0.016 1 4 1 - Type V non-mosaic L421P - S91F,D95A S87R V57M G A39T -
7079 2019 9363 6765 0.125 0.008 <0.016 1.5 0.012 1.5 - Type II non-mosaic - G120K,A121N - - V57M G - -
7181 2019 9363 19,731 0.19 0.016 <0.016 3 0.004 1.5 - Type II non-mosaic - G120K,A121N - - V57M G - -
7789 2019 7822 14,994 0.125 0.012 <0.016 0.75 2 1 - Type V non-mosaic L421P S91F,D95A S87R V57M G A39T -
9051 2019 7822 14,994 0.38 0.016 <0.016 1.5 6 1.5 - Type V non-mosaic L421P - S91F,D95A S87R V57M G A39T -
P: penicillin; CRO: ceftriaxone; CFM: cefixime; TET: tetracycline; CIP: ciprofloxacin; AZ: azithromycin; nd: no data available; -: wild type. a: G, deletion of one G (guanine), 20 nucleotides downstream of where
the -35A deletion occurs.
Pharmaceutics 2021, 13, 1699 8 of 15
Whole-genome SNP-based phylogenetic analysis of the 35 sequenced isolates revealed
a great genetic dissimilarity between isolates, with differences ranging from 0 to 2378 SNPs;
however, three clades involving non-azithromycin-susceptible isolates were identified
(Figure 1). Clade 1 consisted of three isolates belonging to MLST ST-7822, with an Ala39Thr
substitution in the MtrR gene and a deletion of one G, 20 nucleotides downstream of where
the -35A deletion occurs; no SNP differences were observed. Clade 2 consisted of two
isolates belonging to MLST ST-1580, with the C2599T mutation in the 23S rRNA gene and
a Gly45Thr substitution in the MtrR gene; no SNP differences were observed. Clade 3
consisted of eight closely related isolates belonging to MLST ST-9363, with a deletion of
one G, 20 nucleotides downstream of where the -35A deletion occurs; differences between
these isolates ranged from 0 to 20 SNPs. The same three clusters were obtained when the
phylogenetic tree was constructed from the whole genome (data not shown).
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3.4. Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis
Figure 2 shows the probability of target attainment (PTA) values of all of the antimicro-
bial agents studied, as well as their MIC distribution. On the basis of the simulation results,
and taking into account the targets for the different antimicrobial agents, PTA values equal
to or higher than 90% were achieved with (1) azithromycin at single doses of 1 g and 2 g,
for MICs up to 0.064 and 0.125 mg/L, respectively; (2) ceftriaxone at 250, 500, and 1000 g,
administered intramuscularly as single doses, for MICs up to 0.064, 0.125, and 0.25 mg/L,
respectively, and for MICs equal to or lower than 1 mg/L fo 2 g/day via the intravenous
route; (3) cefixime at 400 mg/day by oral route, for MICs up to 0.125 mg/L; and (4) single
oral doses of ciprofloxacin at 500 mg, for MICs up to 0.125 mg/L.
Table 4 features the CFR values obtained after the PK/PD analysis and Monte Carlo
simulations. Values higher than 90% were only achieved with the two cephalosporins.
In Supplementary Tables S2–S9, the mean, median, and 2.5% and 97.5% confidence
intervals of PTA and CFR for every antimicrobial and dosing regimen are presented.
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Table 4. Cumulative fraction of response (CFR) calculated for all antibiotics and dosing regimens.
Antibiotic Dosing Regimen CFR (%)
Ciprofloxacin 500 mg, single dose, PO 51
Azithromycin 1 g single dose, PO 33
2 g single dose, PO 64
Ceftriaxone
1 g, single dose, IM 100
500 mg, single dose, IM 98
250 mg, single dose, IM 96
2 g/day, IV 100
Cefixime 400 mg/day, PO 97
PO: oral administration; IM: intramuscular; IV: intravenous.
4. Discussion
To address the antimicrobial resistance problem, more efficient means of evaluating
therapies for gonorrhea are needed. Our purpose in this study was to apply molecular
epidemiology—including whole-genome sequencing (WGS) information, antimicrobial
surveillance data, and PK/PD analysis—to guide the antimicrobial treatment of gonococci
infections in the Basque Country (Spain).
In this region of the north of Spain, the percentage of resistance was of the same order
as recent data obtained from Madrid [20] and Barcelona [21,22], and also of those reported
in other European countries [23]. As expected, the highest percentage of resistance was
detected for ciprofloxacin (>45%). The historical resistance of gonococci to ciprofloxacin is
very well known, and it has been related to the incidence of gonorrhea at the population
level. In fact, ciprofloxacin is no longer recommended for treatment of this STI, except
for pharyngeal infections if susceptibility has been proven or if the patient is allergic to
β-lactams [9].
In spite of the differences in the resistance breakpoint between EUCAST [13] and
CLSI [14] for ciprofloxacin (0.125 and 1 mg/L, respectively), the percentage resistance
we obtained was similar, since very few isolates are affected by the discrepancies in the
breakpoints (Figure 1). However, discrepancies in the clinical breakpoint for cephalosporins
(0.25 mg/L from EUCAST and 0.5 mg/L from CLSI) justify the difference in the percentage
resistance for cefixime (6.5% vs. 1.6%) and ceftriaxone (2.0% vs. 0.5%). Unlike the other
antibiotics, all isolates resistant to azithromycin were collected in 2019 (n = 11). These data
are consistent with the recent increase in the resistance of N. gonorrhoeae to azithromycin in
Spain and worldwide [22,23]. Some studies support the notion that the selection/induction
of azithromycin resistance in N. gonorrhoeae may be associated with the general use of
azithromycin for the treatment of respiratory infections or non-gonococcal urethritis [24].
According to the susceptibility profile, azithromycin and cephalosporins are the most
active antimicrobials. These results are in agreement with the European guidelines, which
recommend the use of a dual therapy with ceftriaxone and azithromycin for all gonorrhea
cases [7].
Antibiotic susceptibility data were consistent with those obtained through WGS,
and the mutations detected were related to resistance to the studied antibiotics. The
genomic study detected the main antimicrobial resistance determinants associated with
resistance to β-lactams (penA, porB, ponA, mtrR, and blaTEM1-B), ciprofloxacin (gyrA and
parC), and tetracycline (tetM and rpsJ). All ciprofloxacin-resistant strains presented two
substitutions in GyrA, together with substitutions in the ParC protein, while among the
ciprofloxacin-susceptible isolates, no mutations in the gyrA and parC genes were detected,
as previously reported [25]. Regarding ceftriaxone—and as expected—the mutations found
in the analyzed resistant isolates were associated with reduced susceptibility or resistance
to ESC [26]. Tetracycline resistance in N. gonorrhoeae may be related to the presence of the
plasmid-mediated TetM protein (MIC, 16–64 mg/L), or to mutations in some chromosomal
genes (MIC, 2–4 mg/L) [27,28]. In our study, the tetM gene was detected only in high-level
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resistant isolates; meanwhile, low-level resistant isolates only presented mutations in the
chromosomal genes penB (PorB), rpsJ (S10), and mtrR and its promoter. These isolates
presented at least two or three mutated genes, suggesting that more than one antimicrobial
resistance determinant is needed to confer resistance.
Resistance to β-lactams, macrolides, and tetracycline may result from overexpression
of the MtrCDE efflux pump related to mutations in the promoter and/or coding regions of
the mtrR repressor, which causes not only resistance, but also an increase in the MIC [25].
The -35A deletion in the promoter sequence—the most common mutation—was detected
only in isolates recovered in 2017 and 2018, but it was not observed in those from 2019.
Several mutations—including insertions, deletions, or transversions—have been described
in this promoter region [29]. Related to azithromycin resistance, a guanine (G) deletion in
this promoter was observed in most of the azithromycin-resistant isolates, either alone or
associated with the A39T substitution in MtrR repressor. In some isolates, this mutation
was associated with substitutions in the MtrD protein (data not shown), so the exact
contribution of this G deletion to antimicrobial resistance should be determined.
The majority of genotyped azithromycin-resistant isolates were MLST ST-9363. In
a recent study carried out in Barcelona (Spain) [22], this genotype was associated with
outbreaks of N. gonorrhoeae with high-level azithromycin resistance (MIC ≥ 256 mg/L)
between 2016 and 2018. In that study, this genotype was found mainly in men who have
sex with men. Contrary to Barcelona isolates, our ST-9363 isolates were not high-level
azithromycin resistant, and their MIC values were 1 and 2 mg/L. The phylogenetic analysis
of both the SNPs and the complete genome using the WGS showed similar results and,
together with the application of the other epidemiological markers and antibiotic resistance,
allowed the epidemiological characterization of the strains analyzed. The joint analysis of
the data obtained from the WGS allowed the detection of three clusters that involved eight,
three, and two non-azithromycin-susceptible isolates, respectively, all of them isolated in
2019 and with an MIC ≥ 1 mg/L to azithromycin.
Among the interventions to mitigate the current and future impact of antimicrobial re-
sistance, the development of new generations of antimicrobials is one of the most accepted.
Another recognized strategy to diminish antibiotic resistance is the optimization of the
dosing regimen of available antimicrobials. PK/PD analysis and Monte Carlo simulation
have shown to be very useful tools to select adequate antibiotic dosages, with the goal of
increasing treatment efficacy and reducing the risk of multidrug-resistant pathogens [30].
Although integrated PK/PD analysis has been applied to identify changes in the antimi-
crobial activity of antibiotics [31,32], until now it has not been applied to gonorrhea for
optimizing dosage and correlating exposure with clinical outcomes [33]. Therefore, by
using Monte Carlo simulation, we evaluated the probability of PK/PD target attainment by
MIC (PTA), as well as taking into account the MIC distribution (CFR), which is indicative
of treatment success.
At EUCAST susceptibility breakpoints, all antibiotics except for azithromycin and the
lowest dose of ceftriaxone provided high (>90%) probability of treatment success (Figure 2).
Moreover, the highest doses of ceftriaxone also showed adequate results for higher MICs
(1 g IM would cover an MIC of 0.25 mg/L, and 2 g/day IV would cover an MIC of 1 mg/L).
Regarding azithromycin in monotherapy, 1 g would be an option only when the MIC is
0.064 mg/L or lower, and 2 g if the MIC is equal to or lower than 0.125 mg/L.
Empirical treatments with antimicrobial drugs (i.e., without susceptibility testing)
provide progressive development of decreasing susceptibility, which threatens personal
and public health. The estimation of CFR is a very useful tool to guide empirical treatments,
since it allows us to know which antimicrobial and dose regimen would have the best like-
lihood of success to treat bacterial isolates from a particular hospital or geographical area.
Considering the MIC distribution of our isolates, CFR values—indicative of the probability
of empirical treatment success (Table 4)—allow us to confirm that ceftriaxone (even at the
lowest dose: 250 mg) and oral cefixime are good candidates to empirically treat gonorrhea
(CFR around 100%) in our geographical area. On the other hand, ciprofloxacin should
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not be used empirically. For both ESCs and ciprofloxacin, the probability of treatment
success was correlated with the susceptibility rate. However, the susceptibility rate of
azithromycin was much higher than the estimated CFR. This discrepancy may be explained
in part by the fact that, in contrast to β-lactams—which do not accumulate within the cell
(extracelluar: intracellular ratio of 1)—azithromycin achieves intracellular concentrations
several-fold higher than in plasma and extracellular fluid [34]. Taking into account that N.
gonorrhoeae presents intracellular localization, the treatment success of azithromycin may
be underestimated.
Our results are consistent with the European guidelines for the diagnosis and treat-
ment of gonorrhea in adults [7], and with the CDC [8], both of which recommend ceftriax-
one monotherapy for the treatment of uncomplicated gonorrhoeae. Because N. gonorrhoeae
remains highly susceptible to ceftriaxone, and azithromycin resistance is increasing, pru-
dent use of antimicrobial agents supports limiting their use. In spite of that, continuous
monitoring for the emergence of resistance to this cephalosporin is necessary in order to
ensure the efficacy of the recommended regimens. In this sense, surveillance programs and
health care provider reports of treatment failures are essential.
For empirical treatment, the WHO recommends that the selected gonorrhea treatment
should have ≥95% probability of being effective—that is, 5% or fewer of gonococcal isolates
are likely to be resistant to the antimicrobial used for first-line empirical treatment [35].
In our opinion, PK/PD analysis must be also considered; in this sense, the selection of
the most adequate antibiotic and dosing regimen should be based on local epidemiology.
Moreover, PK/PD analysis results are also beneficial when the MIC value is known, and
in the case of ceftriaxone, would allow the selection of lower doses. In previous studies,
PK/PD analysis has been shown to be a useful tool for the surveillance of antimicrobial
activity, as a complement to the simple assessment of MIC values [32,36–38]. Thus, it could
be applied to guide therapy along with surveillance programs of gonococcal resistance. In
this sense, the surveillance of gonococcal antimicrobial resistance could be implemented
with PK/PD analysis by using the susceptibility data collected by the Euro-GASP.
This study presents some limitations. First, PK/PD analysis was performed by using
the mean and standard deviation of the PK parameters, without considering the potential
influence of covariates on the PK profile; second, our simulations are based on plasma con-
centrations and, therefore, dosing recommendations may be more beneficial for gonococcal
bacteremia than for extragenital infection.
In spite of these limitations, our study represents a good example of how to combine
molecular epidemiology, antimicrobial surveillance, and PK/PD analysis to provide quality
data to support treatment guidelines—especially empirical treatments.
5. Conclusions
In our geographical area, multiple distinct populations of N. gonorrhoeae were identi-
fied. We can confirm that ceftriaxone (even at the lowest dose: 250 mg) and oral cefixime
are good candidates to treat gonorrhea. For patients allergic to β-lactam antibiotics, or with
pharyngeal infections, ciprofloxacin should be only used if the MIC is known and is equal
to or lower than 0.125 mg/L; this antimicrobial is not recommended to be used empirically.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13101699/s1, Figure S1: MIC frequency of all antimicrobials studie. Figure S2:
Alignment of partial sequences of the mtrR promoter from Neisseria gonorrhoeae FA1090 (GenBank
accession number NC_002946), Neisseria gonorrhoeae 38197 (GenBank accession number KT954125),
and some N. gonorrhoeae isolates from this study. The -10 and -35 promoter sequences for the
mtrR gene are shown in overlines. The 13-bp inverted repeat (IR) is underlined. Lowercase letters
represent the single-base-pair deletion (-35A Del) within the IR. *—location of the single base-pair
deletion (G) 20 nucleotides downstream of where the -35A deletion occurs; Table S1: Dose regimen,
PK/PD index, and pharmacokinetic parameters used for simulations; Table S2: Probability of target
attainment (PTA) and cumulative fraction of response (CFR) of ciprofloxacin, 500 mg, single dose,
oral administration; Table S3: Probability of target attainment (PTA) and cumulative fraction of
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response (CFR) of azithromycin, 1 g, single dose, oral administration; Table S4: Probability of target
attainment (PTA) and cumulative fraction of response (CFR) of azithromycin, 2 g, single dose, oral
administration; Table S5: Probability of target attainment (PTA) and cumulative fraction of response
(CFR) of ceftriaxone, 250 mg, single dose, intramuscular administration; Table S6: Probability of
target attainment (PTA) and cumulative fraction of response (CFR) of ceftriaxone, 500 mg, single
dose, intramuscular administration; Table S7: Probability of target attainment (PTA) and cumulative
fraction of response (CFR) of ceftriaxone, 1 g, single dose, intramuscular administration; Table S8:
Probability of target attainment (PTA) and cumulative fraction of response (CFR) of ceftriaxone,
2 g/day, intravenous administration; Table S9: Probability of target attainment (PTA) and cumulative
fraction of response (CFR) of cefixime, 400 mg/day, oral administration.
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